


MAIS ALGARVE NA EUROPA LIDERANÇA INDUSTRIAL /DESAFIOS SOCIETAIS

Alterações Demográficas e Bem – Estar

Joana Camilo (NCP) | FCT (GPPQ)

NCP para o Desafio Saúde, European Research Council (ERC) e Infra-estruturas de Investigação




HORIZONTE 2020 | Apoio à Investigação & Inovação



➤ **Enfoque nos desafios sociais** da UE, alterações climáticas, sustentabilidade/competitividade, segurança energética e alimentar, envelhecimento saudável,.....

1. **Saúde**, alterações demográficas e bem-estar
2. **Segurança alimentar**, agricultura e silvicultura sustentáveis, investigação marinha, marítima e águas interiores e a bioeconomia
3. **Energia** segura, eficiente e sustentável
4. **Transportes** inteligentes, verdes e integrados
5. **Ação Climática, ambiente**, eficiência de recursos e matérias primas
6. A Europa num Mundo em mudança - **Sociedades inclusivas, inovadoras e pensadoras**
7. **Sociedades seguras**- proteção da segurança da Europa e dos seus cidadãos

Do 7º Programa-Quadro [2007, 2013] ao HORIZONTE 2020 [2014, 2020]



Mudança de paradigma

- ✓ **Abordagem holística** baseada em desafios
- ✓ Investigação **trans-, multi- e interdisciplinar**
- ✓ Projectos orientados para o **mercado**
- ✓ Exploração dos resultados de I&DT – **cobertura de todo o ciclo de inovação**
- ✓ **Ciências sociais e humanidades** – presença ‘transversal’
- ✓ Tópicos mais abertos/abrangentes – “competição entre patologias”

4 /10 Temas 7PQ:

ENV – Ambiente | **ICT** – Tecnologias da Comunicação e Informação


NMP – Nanociências, Nanotecnologias, Materiais e Novas Tecnologias de Produção

SSH – Ciências Socioeconómicas e Humanidades

Oportunidades de Financiamento no HORIZONTE 2020 para o Algarve



HORIZONTE 2020 | Programação estratégica - ciclo de programas de trabalho



Alguns princípios

- ✓ Programa de Trabalho 2+1 anos: perspectivas
- ✓ desenvolvimento orientado por Programa Estratégico



Programação estratégica → 12 *Focus areas*

Desafio Societal Saúde (DS1) <-> Personalising health and care

MEDICINA
E
CUIDADOS
PERSONALIZADOS?



Programação estratégica → Focus area: Personalising health and care (I)


HOME ABOUT INSIGHTS OBSERVATORY EUROBIOFORUM 2013

EUROBIOFORUM
 Forum for research funders and performers in Personalised Medicine

NETHERLANDS

Strengthen transatlantic cooperation in Personalized Medicine

1st Transatlantic Conference on Personalized Medicine



For reprint orders, please contact: reprints@futuremedicine.com

Enabling personalized medicine in Europe: a look at the European Commission's funding activities in the field of personalized medicine research

SPECIAL REPORT



NATURE | EDITORIAL

Getting personal

Nature 478, 253–254 (19 May 2011) | doi:10.1038/473253a
 Published online: 18 May 2011

PDF Citation Reprints Rights & permissions Article metrics

targeted therapies work, but need help to fulfil their potential.

Subject terms: Cancer • Disease • Health and medicine

Biology is like economics, participants at a European Commission meeting on personalized medicine in Brussels heard last week: they are both complex and neither is properly understood. The view struck a chord with attending scientists and health-care economists, who felt that personalized medicine should be happening, and didn't understand why, mostly, it isn't.

Personalized medicine aims to use the latest genomic knowledge and technologies to tailor treatments to individuals. Pivotal to the field are drugs that have been designed to hit a particular

The potential benefits that personalized medicine approaches can bring to healthcare are discussed with much interest throughout the EU. This novel approach is based on a better understanding of the molecular mechanisms of health and disease and it has now begun to show results. There is, however, a long way to go before the area is fully exploited. This special report reviews the European Commission's funding activities related to personalized medicine research. Although the specific focus on personalized medicine is relatively new, the European Commission has already committed significant funding to research in enabling technologies relevant to the field, as well as to specific disease areas for their application. A stocktaking exercise which started in 2010 has helped identify immediate and future challenges in personalized medicine research. The outcomes of this exercise, summarized below, will contribute to developing a vision for future research funding at the EU level.

KEYWORDS: biomarkers • diagnostics • education and training • enabling technologies • EU Horizon 2020 • personalized medicine • pharmacogenomics • rare diseases • Seventh Framework Programme

Alexandra Draghici-Akli
 Health Director, Directorate-General for Research & Innovation, European Commission, Brussels
alexandra.draghici-akli@ec.europa.eu

The goal of medicine has always been to provide the best possible care for patients. Personalized medicine promises to advance this goal further by employing a "medical model using molecular profiling techniques for tailoring the right therapeutic strategy for the right person at the right time, and determine the predisposition to disease and to deliver timely and stratified prevention".

Major benefits can be expected for patients in terms of increased efficiency and less adverse reactions to prescribed treatments. Personalized medicine may also have positive impacts on healthcare costs. Although stratifying patients into subgroups, sharing the same molecular characteristics as a first step to personalized approaches, is already practiced in some therapeutic areas, such as cancer and HIV/AIDS, significant research and development efforts are needed across the full innovation chain in many other medical areas. This includes basic research through the digital development phase to health economics.

Enabling research at the European level
 To gain a better understanding of the key research needs for the development of personalized medicine approaches, the European Commission's (EC) Personalized Medicine Unit in the Health Research Directorate organized the conference *European Perspectives in Personalized Medicine*. The conference, held in

Brussels on 12–13 May 2011, attracted some 450 participants from across Europe and beyond. The EC has committed significant funding over the last 5-year period (2007–2011) via the Health Theme of the *Seventh EU Framework Programme for Research and Technological Development* (FP7) to research enabling the development of personalized medicine approaches. Collaborative projects harnessing talents from the EU and around the globe have received some €900 million in support of research and development in the following domains: tools and technologies for high-throughput research; new diagnostic development and large-scale data gathering, in particular for "omics" research such as genomics, proteomics, metabolomics and epigenomics. Several EU funded collaborative projects aim at developing genetic tools and knowledge that should impact directly on progress in personalized medicine for major diseases such as cardiovascular disease, CNS disease and cancer. Advances are expected in the identification of susceptibility genes to predict disease, novel targets to overcome drug resistance and biomarkers to stratify patient populations in subgroups. Additional projects are specifically developing stratified or personalized approaches to breast, colorectal, renal, adrenal and lung cancer (see...)

Other projects aim to structure and support European participation in large-scale international research collaborations. In these endeavors, where vast amounts of data are gathered



Roche Personalised Healthcare – our mission



Roche Personalised Healthcare – our structure



Roche Personalised Healthcare – our achievements



Impact on laboratory medicine today and tomorrow



Contexto temático – Programação estratégica → Focus area: *Personalising health and care*

Policy issues



Personalised medicine conferences and workshops

2011 Conference
European Perspectives in Personalised Medicine
 Square-Brussels Meeting Centre, Brussels, Belgium - 12-13 May 2011.

2010 Workshops
Personalised Medicine - Opportunities and Challenges for European Healthcare
 European Health Forum, Gastein, Austria - 07 October 2010

Stratification Biomarkers in Personalised Medicine
 European Commission, DG Research - Brussels, Belgium - 10-11 June 2010

-Omics in Personalised Medicine
 European Commission, DG Research - Brussels, Belgium - 29-30 April 2010

4D Biology for Health and Disease
 European Commission, DG Research - Brussels, Belgium - 16-17 March 2010

http://ec.europa.eu/research/health/events-06_en.html



For reprint orders, please contact: reprints@futuremedicine.com

SPECIAL REPORT

Enabling personalized medicine in Europe: a look at the European Commission's funding activities in the field of personalized medicine research

The potential benefits that personalized medicine approaches can bring to healthcare are discussed with much interest throughout the EU. This novel approach is based on a better understanding of the molecular mechanisms of health and disease and it has now begun to show results. There is, however, a long way to go before the area is fully exploited. This special report reviews the European Commission's funding activities related to personalized medicine research. Although the specific focus on personalized medicine is relatively new, the European Commission has already committed significant funding to research in enabling technologies relevant to the field, as well as to specific disease areas for their application. A stocktaking exercise which started in 2010 has helped identify immediate and future challenges in personalized medicine research. The outcomes of this exercise, summarized below, will contribute to developing a vision for future research funding at the EU level.

KEYWORDS: biomarkers diagnostics education and training enabling technologies EU Horizon 2020 personalized medicine pharmacogenomics rare diseases Seventh Framework Programme

Alexandra Draghici-Akli
 Health Director, Directorate
 General for Research & Innovation,
 European Commission, Brussels,
 Belgium
alexandra.draghici-akli@ec.europa.eu

The goal of medicine has always been to provide the best possible care for patients. Personalized medicine promises to advance this goal further by employing a "medical model using molecular profiling technologies for tailoring the right therapeutic strategy for the right person at the right time, and determine the predisposition to disease and to deliver timely and stratified prevention" [1]. Major benefits can be expected for patients in terms of increased efficiency and less adverse reactions to prescribed treatments. Personalized medicine may also have positive impacts on healthcare costs. Although stratifying patients into subgroups, sharing the same molecular characteristics as a first step to personalized approaches, is already practiced in some therapeutic areas, such as cancer and HIV/AIDS, significant research and development efforts are needed across the full innovation chain in many other medical areas. This includes basic research through the digital development phase to health economics.

Enabling research at the European level

To gain a better understanding of the key research needs for the development of personalized medicine approaches, the European Commission's (EC) Personalized Medicine Unit in the Health Research Directorate organized the conference *European Perspectives in Personalized Medicine*. The conference, held in

Brussels on 12–13 May 2011, attracted some 450 participants from across Europe and beyond. The EC has committed significant funding over the last 5-year period (2007–2011) via the Health Theme of the *Seventh EU Framework Programme for Research and Technological Development* (FP7) [2] to research enabling the development of personalized medicine approaches. Collaborative projects harnessing talents from the EU and around the globe have received some €300 million in support of research and development in the following domains: tools and technologies for high-throughput research; new diagnostics development and large-scale data gathering, in particular for "omics" research such as genomics, proteomics, metabolomics and epigenomics. Several EU funded collaborative projects aim at developing genetic tools and knowledge that should impact directly on progress in personalized medicine for major diseases such as cardiovascular diseases, CNS diseases and cancer. Advances are expected in the identification of susceptibility genes to predict disease, novel targets to overcome drug resistance and biomarkers to stratify patient populations in subgroups. Additional projects are specifically developing European participation in large-scale international research collaborations. In these endeavors, where vast amounts of data are gathered

Programação estratégica → Focus area: *Personalising health and care* (II)

Personalising health and care

A combination of the immediate effects of the economic crisis, an ageing European population and an increasing chronic disease burden are jeopardising the sustainability and equity of European health and care systems, on which Europe already spends more than 9.5% GDP. Breakthrough research and radical innovation are required now to address the challenge, as is the translation of findings into the clinic and other health and care settings to improve health outcomes, reduce health inequalities and to promote active and healthy ageing. In order to do so, this focus area will support research and innovation throughout the health and care chain by promoting the development of personalised diagnostics, drugs and other interventions in an optimised and risk sharing approach, by empowering citizens to be active and engaged in managing their health and wellbeing for as long as possible, by improving health and care delivery through measures including evidence based integrated and self-care, and by promoting population health interventions, including adapting to changing environmental and climate factors. Doing so requires the engagement of a variety of stakeholders working in partnership, whether through the Innovative Medicines Initiative bringing together academia, small businesses and the research based pharmaceutical industry; through the Ambient Assisted Living Joint Programme with Member States bringing together users, small businesses, academia and the ICT and service industry; through direct support to small businesses to bring their products and services to market, or through other forms of co-operation research, including international and Public-Public partnerships. Biomedical research innovation in these areas has the potential not only to improve quality of life, but also to deliver new jobs and growth (biomedical research industries provide a significant proportion of EU R&D business investment, the global tele-care and tele-health



**Apoio às
políticas UE**

Health Strategy; the Health Security Initiative; the eHealth Action Plan 2012-2020; the European Innovation Partnership on Active and Healthy Ageing as well as policy development necessary for the implementation of personalised approaches, for health and care system sustainability.

Programação estratégica → Preparação dos Programas de Trabalho (WP)

Plataformas Tecnológicas Europeias (ETPs)

- Nanomedicine

Advisory Groups

- MI Scientific Committee: Beatriz Lima, FFUL
- DS1 (Saúde): Paula Alves, Paolo Lisboa

Iniciativas Europeias

- *Joint Programming Initiatives (JPIs)*
JPND, HDHL, MYBL, JPIAMR
- *European Innovation Partnerships (EIPs) - AHA*
- *Joint Technology Initiatives (JTI) – IMI*

Policy DGs (SANCO, DEVCO, ENTR,...)


Apoio a estratégias e políticas UE

Continuidade/complementaridade com estudos/projectos anteriores

Identificação de lacunas ou necessidades de investigação, *inputs* de stakeholders

Acordos de cooperação bilateral/internacional

Origem dos tópicos de Investigação?



Desafio Societal e Alterações Demográficas e Bem estar

Objectivos

Saúde e bem-estar ao longo da vida, para todos
Sistemas de saúde e sociais de qualidade e economicamente sustentáveis,
oportunidades para novos empregos e crescimento
Contribuição para a Estratégia Europa

relacionado

Actividades

- 1 Understanding health, well-being and disease
- 2 Preventing disease
- Treating and managing disease
- 4 Active ageing and self-management of health
- Methods and data
- 6 Health care provision and integrated care



Estratégia Europeia de Inovação para as Atividades da Vida e da Saúde

http://ec.europa.eu/research/innovation-union/index_en.cfm#section_active-healthy-ageing




Triple win for Europe:

- *enabling EU citizens to lead healthy, active and independent lives while ageing;*
- *improving the sustainability and efficiency of social and health care systems;*
- *boosting and improving the competitiveness of the markets for innovative products and services, responding to the ageing challenge at both EU and global level, thus creating new opportunities for businesses*

A meta-estratégia para a melhoria da saúde

grandes áreas





Principais Ações

- [Prescription and adherence action at regional level](#)
- [Falls Prevention](#)
- [Prevention of functional decline and frailty](#)
- [Integrated Care](#)
- [Independent Living](#)
- [Age-friendly Environments](#)

Perspectivas de financiamento para o Programa de Trabalho P - I

etter health for all

Medicina e cuidados personalizados





**HORIZON 2020
WORK PROGRAMME 2014 – 2015**

8. Health, demographic change and wellbeing

Important Notice on the First Horizon 2020 Work Programme

This Work Programme covers 2014 and 2015. Due to the launching phase of Horizon 2020, parts of the Work Programme that relate to 2015 (topics, dates, budget) are provided at this stage on an indicative basis only. Such Work Programme parts will be decided during 2014.

(European Commission Decision C (2013)8631 of 10 December 2013)

HORIZON 2020 – WORK PROGRAMME 2014-2015
Health, demographic change and wellbeing

Personalising health and care	7
Understanding health, ageing and disease.....	7
PHC 1 – 2014: Understanding health, ageing and disease: determinants, risk factors and pathways.....	7
PHC 2 – 2015: Understanding diseases: systems medicine.....	8
PHC 3 - 2015: Understanding common mechanisms of diseases and their relevance in co-morbidities.....	9
Effective health promotion, disease prevention, preparedness and screening.....	10
PHC 4 – 2015: Health promotion and disease prevention: improved inter-sector co-operation for environment and health based interventions.....	10
PHC 5 – 2014: Health promotion and disease prevention: translating ‘omics’ into stratified approaches.....	11
PHC 6 – 2014: Evaluating existing screening and prevention programmes.....	12
PHC 7 – 2014: Improving the control of infectious epidemics and foodborne outbreaks through rapid identification of pathogens (see also societal challenge 2).....	13
PHC 8 – 2014: Vaccine development for poverty-related and neglected infectious diseases: Tuberculosis.....	15
PHC 9 – 2015: Vaccine development for poverty-related and neglected infectious diseases: HIV/AIDS.....	16
Improving diagnosis.....	18
PHC 10 – 2014: Development of new diagnostic tools and technologies: <i>in vitro</i> devices, assays and platforms.....	18
PHC 11 – 2015: Development of new diagnostic tools and technologies: <i>in vivo</i> medical imaging technologies.....	19
PHC 12 – 2014/2015: Clinical research for the validation of biomarkers and/or diagnostic medical devices.....	20
Innovative treatments and technologies.....	22
PHC 13 – 2014: New therapies for chronic non-communicable diseases.....	22
PHC 14 – 2015: New therapies for rare diseases.....	23
PHC 15 – 2014/2015: Clinical research on regenerative medicine.....	24
PHC 16 – 2015: Tools and technologies for advanced therapies.....	25
PHC 17 – 2014: Comparing the effectiveness of existing healthcare interventions in the elderly.....	26
PHC 18 – 2015: Establishing effectiveness of health care interventions in the paediatric population.....	28
Advancing active and healthy ageing.....	29



perspectivas de financiamento para o programa de trabalho P

Understanding ealt ageing and disease ()

Effective ealt promotion disease prevention preparedness and screening (6)

Improving diagnosis ()

Innovative treatments and tec nologies (6)

Advancing active and ealt ageing (4)


Integrated sustaina le citi en-centred care ()

Improving ealt information data e ploitation and providing an evidence
ase for ealt policies and regulation (6)

Coordination Activities (1)

n. de t picos

a itali a o de o ortunidades no DS do ara a regi o do gar e



Fonte: CCDR Algarve – RIS3 Regional

Perspectivas de financiamento para o Programa de Trabalho (WP) 2014-2015 (III)

- Determinantes da saúde e doença
- Comorbilidades
- Medicina de sistemas
- Intervenções multisector

- Ferramentas p/a terapias avançadas
- Doenças raras
- Medicina regenerativa
- Eficácia de intervenções

- Aplicação das '-ómicas'
- Programas de screening/ prevenção
- Controlo de epidemias infecciosas
- Desenvolvimento de vacinas

- Diagnóstico in-vivo, imagiologia, e in-vitro

- ICT para cuidados integrados
- ICT para vivência independente
- Robótica para vivência assistida
- ICT para cuidados integrados
- ICT para detecção de riscos

- ICT p/ autogestão da saúde
- mHealth
- Interoperabilidade eHealth
- Paciente Digital
- Medicina personalizada nos sistemas saúde/ cuidados
- Serviços e-HEALTH Inovadores

Validação clínica de biomarcadores

- Bioinformática médica
- Fast Track to Innovation




Perspectivas de financiamento para o Programa de Trabalho (WP) - (II)



Understanding health, ageing and disease ()

P *Understanding the determinants, risk factors and pathways - Research Innovation Action ()*



Innovative treatments and technologies ()

P *Development of innovative healthcare interventions in the elderly - Research Innovation Action ()*

Advancing active and healthy ageing ()

P *Advancing active and healthy ageing through assisted living environments - Research Innovation Action ()*

**T
D
E**

P *Advancing active and healthy ageing through solutions for independent living with cognitive impairment - Research Innovation Action ()*

P *Advancing active and healthy ageing through early risk detection and intervention - Research Innovation Action ()*

P *Promoting mental health in the ageing population - Research Innovation Action ()*



Tópicos de potencial interesse para o Algarve (I)

*PH – ersta i g ealt agei ga isease
etermi a ts ris factors a at a s (RIA, - M)*

*PH – ealt romotio a
isease re e tio im ro e i ter sector
co o eratio fore iro me ta ealt
ase i ter e tio s (RIA, - M)*

*PH – ealt romotio a
isease re e tio tra slati g omics i to
stratifie a roac es (RIA, - M)*



[tt ece ro ae researc ealt lic ealt ealt romotio](#)
[a isease re e tio i e e tml](#)



**A o e
 fi a ciame to**

Specific Challenge:
*Conte to, problemas a resolver,
 necessidade da interven o*

Scope
*Delic a o o ro lema
 especifica o o e fo e e as
 fro teiras a aç o mas sem m ito
 etal e so re as oss eis
 a or age s*

Expected impact
*Descri o os eleme tos c a e a
 alca çar o esafio em est o*

PHC 1 – 2014: Understanding health, ageing and disease: determinants, risk factors and pathways

Specific challenge: The development and preservation of good health, and the occurrence and evolution of common diseases and disabilities result from varying degrees of interaction between the genetic make-up of individual human beings and behavioural, environmental (including endocrine disruptors), occupational, nutritional and other modifiable lifestyle factors. This applies from the earliest stages of development throughout life.

Understanding these factors, their interactions and the extent to which they contribute to health preservation and/or to disease development is important for the development of preventive and therapeutic measures supporting good health, prolonged active independence and a productive working life, not least in the context of changing demographic patterns and the ageing of the European population. In particular, proposals should contribute to improving risk identification and validation, and will allow better diagnosis, risk-based prevention strategies and policies.

Scope:

EITHER:

- i. The identification of health trends and determinants, their validation, and the validation of risk factors for disease and disability through the generation, integration and validation of data social, This assessment val
- Expected impact:
- In both cases, proposals should provide a better understanding of the combined effects of factors causing health and disease, with the knowledge generated underpinning the future development of evidence based prevention, diagnostic, therapeutic and other strategies.

OR:

- ii. The age tim
- For option:
 - i. This should provide evidence for risk identification, underpinning future preventive, diagnostic and therapeutic strategies and policies
- For option:
 - ii. This should provide a better understanding of pathways of healthy ageing, underpinning future strategies for the promotion of healthy ageing, targeted disease prevention and clinical interventions

In both The Co EUR 4 Noneth amoun


Type of action: Research and innovation actions

Temas DS1 1 1 de potencial interesse para o Algarve (II)

PC1 1 : *Development of diagnostic tools and technologies introduced into the platforms (RIA, M)*

PC11 1 : *Development of diagnostic tools and technologies in vivo medical imaging technologies (RIA, M)*

Novos
dispositivos plataformas
ferramentas de diagnóstico



PC1 1 1 : *Biological research for the validation of biomarkers for diagnostic medical devices (SME instrument)*

Tópicos DS1 2014-2015 de potencial interesse para o Algarve (II.1)

Improving diagnosis


PHC 12 – 2014 and 2015) Clinical research for the validation of biomarkers and/or diagnostic medical devices | **SME Instrument**

Âmbito da proposta:

- *Clinical validation of existing potential biomarkers providing evidence for high analytical validity appropriate sensitivity and specificity clinical validity utility*

Impacto esperado:

- Aumento da disponibilidade clínica de biomarcadores e/ou outros dispositivos de diagnóstico para o benefício do paciente
- Crescimento do sector de diagnóstico europeu, em particular das PME
- Apoio implementação da Proposta da CE para a *IVD devices regulation*



Policy issues



Personalised medicine conferences and workshops

2011 Conference

European Perspectives in Personalised Medicine

Square-Brussels Meeting Centre, Brussels, Belgium - 12-13 May 2011.



Conferences & Workshops

2010 Workshops

Personalised Medicine - Opportunities and Challenges for European Healthcare

European Health Forum, Gastein, Austria - 07 October 2010



Videos & Media

Stratification Biomarkers in Personalised Medicine

European Commission, DG Research - Brussels, Belgium - 10-11 June 2010



Contact Corner

The workshop "**Stratification Biomarkers in Personalised Medicine**" aimed to explore issues associated with stratification biomarkers in the emerging field of personalised medicine. The main results of the workshop were to identify obstacles associated to biomarker discovery and to their use in clinical trials and medical practice, to contribute to building a vision for 2020 and to clarify the role of EU-funded research for progressing this rapidly emerging area of research.

Read more in this [Summary Report](#) (149KB)

-Omics in Personalised Medicine

European Commission, DG Research - Brussels, Belgium - 29-30 April 2010



5) Identification of research bottlenecks

Several bottlenecks have been identified:

PHC 11 – 2014 and 2015) Clinical validation of biomarkers

Specific challenge:

- Biomarkers are used in clinical practice to describe both normal and pathological conditions. They can also have a prognostic or a predictive power. They are therefore increasingly used in medicine and many potential biomarkers are proposed every year.
- Only a few of them are however validated for use in a clinical setting. Such validation implies the demonstration of a link to a pertinent clinical endpoint or process, as well as a robust and appropriate analytical method.
- The clinical validation of biomarkers will be increasingly important for the development of new diagnostics, and this is an area where many small European companies are active.

Scope:

- The clinical validation of existing potential biomarkers (not the identification of new ones) is sought. This validation should provide evidence for: high analytical validity; appropriate sensitivity and specificity; clinical validity/ utility.
- Both *in vivo* and *in vitro* potential biomarkers are eligible. Preference will be given to disease related biomarkers (i.e. diagnostic, susceptibility/risk, monitoring and prognostic biomarkers)

Expected impact:

- Increased clinical availability and exploitation of biomarkers for the benefit of the patient.
- Facilitation of entry of improved diagnostics in the clinic and the market.
- Support for the implementation of the Commission proposal for a revised In vitro diagnostic devices regulation².
- Growth of the European diagnostics sector, in particular SMEs

Type of action: SME instrument



Outras informações (I)



Tabela: Listagem dos tópicos 2014 do Programa de Trabalho (WP) 2014-2015 do Desafio Societal Saúde, Alterações Demográficas e Bem-estar" (DS1) do HORIZONTE 2020

Concursos DS1 2014 (549,30M€)	Ref.º tópico	Título do tópico	Instrumento (tipo de projecto)	Financiamento 2014		
				M€ por projecto	N.º de projectos	Orçamento (M€)
PERSONALISING HEALTH AND CARE: H2020-PHC-2014-two-stage (303 M€) Data limite (1ª fase)*: 11 Março 2014 (17h00 de Bruxelas)	PHC-01-2014	Understanding health, ageing and disease: determinants, risk factors and pathways	RIA (100%)	4-6	vários	54
	PHC-05-2014	Health promotion and disease prevention: translating 'omics' into stratified approaches	RIA (100%)	4-6	vários	24
	PHC-06-2014	Evaluating existing screening and prevention programmes	RIA (100%)	2-3	vários	15
	PHC-10-2014	Development of new diagnostic tools and technologies: in vitro devices, assays and platforms	RIA (100%)	4-6	vários	48
	PHC-13-2014	New therapies for chronic non-communicable diseases	RIA (100%)	4-6	vários	60
	PHC-17-2014	Comparing the effectiveness of existing healthcare interventions in the elderly	RIA (100%)	4-6	vários	48
	PHC-23-2014	Developing and comparing new models for safe and efficient, prevention oriented health and care systems	RIA (100%)	4-6	vários	30
PHC-32-2014	Advancing bioinformatics to meet biomedical and clinical needs	RIA (100%)	2-3	vários	24	
PERSONALISING HEALTH AND CARE: H2020-PHC-2014-single-stage (185,2M€) Data limite: 15 Abril 2014 (17h00 de Bruxelas)	PHC-7-2014	Improving the control of infectious epidemics and foodborne outbreaks through rapid identification of pathogens	RIA (100%)	15-20	1	15+5(DS2)
	PHC-8-2014	Vaccine development for poverty-related and neglected infectious diseases: tuberculosis	RIA (100%)	15-25	1	25
	PHC-15-2014	Clinical research on regenerative medicine	RIA (100%)	4-6	vários	36
	PHC-19-2014	Advancing active and healthy ageing with ICT: service robotics within assisted living environments	RIA (100%)	3-4	vários	24,6
	PHC-20-2014	Advancing active and healthy ageing with ICT: ICT solutions for independent living with cognitive impairment	IA (70%**)	2-3	vários	10
	PHC-26-2014	Self management of health and disease: citizen engagement and Health	RIA (100%)	3-5	vários	59,6
	PHC-31-2014	Foresight for health policy development and regulation	RIA (100%)	2-3	~2	6
PHC-34-2014	eHealth interoperability	CSA (< 1 ano)	até 1	vários	4	
HEALTH CO-ORDINATION ACTIVITIES (H2020-HCO-2014) (40M€) Data limite: 15 Abril 2014 (17h00 de Bruxelas)	HCP-01-2014	Support for the European Innovation Partnership on Active and Healthy Ageing	CSA	1-2	1	2
	HCP-02-2014	Joint programming: Co-ordination action for the joint programming initiative (JPI) 'more years better lives the challenges and opportunities of demographic change'	CSA	1-2	1	2
	HCP-04-2014	Support for international infectious disease preparedness research	CSA	2-3	1	3
	HCP-05-2014	Global Alliance for Chronic Diseases: prevention and treatment of type 2 diabetes	RIA (100%)	1-3	1	9
	HCP-07-2014	ERA-NET: Establishing synergies between the Joint Programming on Neurodegenerative Diseases Research and Horizon 2020	ERA-NET Co-fund	5	1	5
	HCP-08-2014	ERA-NET: Aligning national/regional translational cancer research programmes and activities	ERA-NET Co-fund	5	1	5
	HCP-09-2014	ERA-NET: Systems medicine to address clinical needs	ERA-NET Co-fund	5	1	5
	HCP-10-2014	ERA-NET rare disease research implementing IRDIRC objectives	ERA-NET Co-fund	5	1	5
	HCP-14-2014	Bridging the divide in European health research and innovation	CSA	500K€	2	1
HCP-15-2014	Mobilisation and mutual learning action plan	CSA	1	1	1	
H2020-SMEINST-1-2014 (1ª fase) Cut-off dates: 18/06/2014; 4/09/2014; 17/12/2014 (17h00 de Bruxelas)	PHC-12-2014-1	Clinical research for the validation of biomarkers and/or diagnostic medical devices	SME instrument (1ª fase)	50K€	vários	6,61
	PHC-12-2014	Clinical research for the validation of biomarkers and/or diagnostic medical devices	SME instrument (2ª fase)	1-5	vários	58,17



Outras informações (II)

Informação sobre os tópicos/concursos e outros documentos no Portal do participante:

<http://ec.europa.eu/research/participants/portal/desktop/en/opportunities/h.../index.html>

Concursos DS1 2014 (549,30M€)	Ref.º tópico
PERSONALISING HEALTH AND CARE: H2020-PHC-2014-two-stage (303 M€) Data limite (1ª fase) *: 11 Março 2014 (17h00 de Bruxelas)	PHC-01-2014
	PHC-05-2014
	PHC-06-2014
	PHC-10-2014
	PHC-13-2014
	PHC-17-2014
	PHC-23-2014
	PHC-32-2014
PERSONALISING HEALTH AND CARE: H2020-PHC-2014-single-stage (185,2M€) Data limite: 15 Abril 2014 (17h00 de Bruxelas)	PHC-7-2014
	PHC-8-2014
	PHC-15-2014
	PHC-19-2014
	PHC-20-2014
	PHC-26-2014
	PHC-31-2014
	PHC-34-2014

HEALTH CO-ORDINATION ACTIVITIES (H2020-HCO-2014) (40M€) Data limite: 15 Abril 2014 (17h00 de Bruxelas)	HCP-01-2014
	HCP-02-2014
	HCP-04-2014
	HCP-05-2014
	HCP-07-2014
	HCP-08-2014
	HCP-09-2014
	HCP-10-2014
	HCP-14-2014
	HCP-15-2014
H2020-SMEINST-1-2014 (1ª fase) Cut-off dates: 18/06/2014; 4/09/2014; 17/12/2014 (17h00 de Bruxelas)	PHC-12-2014-1
H2020-SMEINST-2-2014 (2ª fase) Cut-off dates: 09/10/2014; 17/12/2014 (17h00 de Bruxelas)	PHC-12-2014



Preparação da proposta | templates



Example of administrative forms and template for the technical annex for proposals for Research and Innovation Actions (RIA) Innovation Actions (IA)

Version 1.0
 11 December 2013

Disclaimer
 This document is aimed at informing potential applicants for Horizon 2020 funding. It serves only as an example. The actual Web forms and templates, provided in the online proposal submission system under the Participant Portal, might differ from this example. Proposals must be prepared and submitted via the online proposal submission system under the Participant Portal.



Limitação do número de páginas por proposta

Oportunidades de financiamento no HORIZONTE 2020 para o Algarve...



Horizon 2020
 Call:
 Topic:
 Type of action:
 Proposal number:
 Proposal acronym:

Proposal template (technical annex)

Research and Innovation actions
 Innovation actions

Table of contents

Section	Title	Action
1	General information	
2	Participants & contacts	
3	Budget	
4	Ethics	
5	Call-specific questions	

How to fill in the forms

The administrative forms must be filled in for each proposal using the templates available in the submission system. Some data fields in the administrative forms are pre-filled based on the previous steps in the submission wizard.



3 - Budget for the proposal

Participant	Country	(A) Direct personnel costs/€	(B) Other direct costs/€	(C) Direct costs of sub-contracting/€	(D) Direct costs of providing financial support to third parties/€	(E) Costs of shared contributions not used on the beneficiary's premises/€	(F) Indirect Costs/€ (40.25(A+B+C))	(G) Special unit costs covering direct & indirect costs	(H) Total eligible expenditure (A+B+C+D+E+F+G)	(I) Contribution rate	(J) Max. grant / € (44%)	(K) Requested grant / €
		0	0	0	0	0	0	0	0	100	0	0
Total		0	0	0	0	0	0	0	0		0	0

CRITÉRIOS de AVALIAÇÃO: *Research and innovation actions, Innovation actions, SME instrument*



<p>1. Excellence</p> <p><i>Note: The following aspects will be taken into account, to the extent that the proposed work corresponds to the topic description in the work programme:</i></p> <ul style="list-style-type: none"> • Clarity and pertinence of the objectives; • Credibility of the proposed approach; • Soundness of the concept, including trans-disciplinary considerations, where relevant; • Extent that proposed work is ambitious, has innovation potential, and is beyond the state of the art (e.g. ground-breaking objectives, novel concepts and approaches). <p><u>Comments:</u></p>	<p>Score 1: Threshold 3/5</p>
---	-----------------------------------

<p>2. Impact</p> <p><i>Note: The following aspects will be taken into account, to the extent to which the outputs of the project should contribute at the European and/or International level:</i></p> <ul style="list-style-type: none"> • The expected impacts listed in the work programme under the relevant topic; • Enhancing innovation capacity and integration of new knowledge; • Strengthening the competitiveness and growth of companies by developing innovations meeting the needs of European and global markets, and where relevant, by delivering such innovations to the markets; • Any other environmental and socially important impacts; • Effectiveness of the proposed measures to exploit and disseminate the project results (including management of IPR), to communicate the project, and to manage research data where relevant. <p><u>Comments:</u></p>	<p>Score 2: Threshold 3/5</p>
--	-----------------------------------

<p>3. Quality and efficiency of the implementation**</p> <p><i>Note: The following aspects will be taken into account:</i></p> <ul style="list-style-type: none"> • Coherence and effectiveness of the work plan, including appropriateness of the allocation of tasks and resources; • Complementarity of the participants within the consortium (when relevant); • Appropriateness of the management structures and procedures, including risk and innovation management. <p><u>Comments:</u></p>	<p>Score 3: Threshold 3/5</p>
--	-----------------------------------

<p>Total score (1+2+3) Threshold 10/15</p>

Outras informações (III)

Entidades Elegíveis a financiamento:

- Qual quer entidade legal estabelecida num EM ou EA ou constituída nos termos do direito da União
- Organizações internacionais de interesse europeu
- As entidades jurídicas estabelecidas num país terceiro identificado no *WP*
- Exceção no Desafio Saúde: participação e financiamento de entidades dos EUA



Panorama Europeu da Investigação e Inovação em Saúde (II)

*Como
começar*



Ferramentas

Outras informações (II)



Apresentações e gravação das sessões á dispon veis

[http //ec.europa.eu/research/health/horizon-2020-health-open-info-da s en html](http://ec.europa.eu/research/health/horizon-2020-health-open-info-days)

Promover e aumenta a participação sustentável do sector industrial da Saúde no H2020

[http // fitforhealth.eu](http://fitforhealth.eu)



Repositório de pro ectos financiados desde 2002 pela ão Europeia, pes uisa por pro ecto, entidade e/ou Investigador

[http // healthcompetence.eu](http://healthcompetence.eu)



Home | What's new? | Policy issues | Ongoing EU research projects | Previous framework programmes | e-Library | **Calls for Proposals**

Horizon 2020 Health Open Info Days



Open Info Day - Horizon 2020 'Health, demographic change and wellbeing'

Centre Albert Borschette, rue Froissart 36, 1040 Brussels, Belgium
Friday 22 November 2013

This event is fully booked – please read the 'You cannot attend the Info Day?' section to find out how you can join and benefit from it anyway


About the event Horizon 2020, the EU's new programme for investment in research and innovation, is expected to include **more than 7 billion EUR** for the 'Health, demographic change and wellbeing' challenge. This event will give you essential information on how to develop a good project proposal, take you through the application process, step by step, and help you find project partners and get answers to your questions. The conference language will be English.

Programme
Download the [draft programme](#) (122KB).

You cannot attend the Info Day?

- Watch it on your computer via the internet - live or after the event. We'll post the necessary links here on time.
- Download all slide presentations soon after the event.
- Contact your [Horizon 2020 'Health' National Contact Point](#) to learn about national info days and other information sources in your country.
- Consider attending the [Horizon 2020 National Launch Events](#) to get a general introduction into the new programme.

Send us your questions
For any question in relation to this event please contact RTD-HEALTH-INFODAY@ec.europa.eu






>>> Sessions 'Funding opportunities for SMEs' and 'From -omics to health promotion':
Do you have specific questions which you would like us to address during these sessions? Please send them prior to the info day to RTD-HEALTH-INFODAY@ec.europa.eu, with the session title workshop in the subject line, to help us prepare these sessions.

>>> Session 'ICT for health and ageing well':
Are you registered for this session and want to make a 3 minute pitch presenting your ideas for a project proposal? Please send your presentation (maximum 3 slides) to CNECT-H2@ec.europa.eu before 15 November. All presentations will be published, but in case more presentations are received than can be presented in the available time, the organisers will make a balanced selection of which pitches will be able to present.

http://ec.europa.eu/research/health/health-open-info-days_en.html

*Apresenta es e v deos dispon veis
Lista de participantes unto do PP*

Overview

Projects (5) »

Font

LIST OF PROJECTS (10 of 87)


10/All Help

	Title	Acronym	Instrument	Number of partners	Project funding	Start date	End date
--	-------	---------	------------	--------------------	-----------------	------------	----------

- 1 Advanced gene th...
CNS-specific diso...
- 2 Advanced Immuniz...
- 3 AIDS VACCINE INT...
- 4 Airway Disease PP...
Patient Specific Co...
- 5 A network for brin...
LIFE
- 6 Applied venomics o...
Conus consors for...
safer and more eth...
biomedical drugs.
- 7 Bio-imaging with Si...
Nanoparticles
- 8 Cancer Genomics o...
- 9 Collaborative Europ...
Diabetes Diagnosti...
- 10 Combined Highly A...
Microbicides

NETWORK GRAPH WITH MAIN PARTNER ORGANISATIONS

Help



Startpage »

Overview

Projects (5)

Persons (6)

Reports

Organisations

Outras fontes de informação sobre os projectos UE de I&DT (I)

6ºPQ [2002, 2006] + 7º PQ [2007, 2013]



European Commission Health Research

Brain Research | Human development and ageing | Cancer | Cardiovascular diseases | Diabetes and obesity | Rare Diseases | Severe Chronic Diseases

General Info | **Calls Info** | Highlights

Medical research in the European Union

One of the objectives of the European Union is to improve the health of European citizens and boost the competitiveness of health-related industries and businesses, while addressing global health issues.

<http://ec.europa.eu/research/health/medical-research/cardiovascular-diseases/projects/en.html>




Home Programme

ICT for Health, Ageing Well, Inclusion and Governance

Participating Projects Newsroom

ICT Information and Communication Technologies

ICT Challenge 5: ICT for Health, Ageing Well, Inclusion and Governance


[Overview](#) | [Projects](#) | [Contact](#)

Projects

This page provides access to information on all up and running ICT projects in challenge 5:

- Personal Health Systems
- Virtual Physiological Human
- ICT for Ageing Well and Inclusion
 - Projects into robotics for rehabilitation and independent living
 - Projects for fall prevention
- Ambient Assisted Living
- ICT for Governance

http://ec.europa.eu/research/environment/index_en.htm#pg_health



RESEARCH & INNOVATION Environment

European Commission Research & Innovation Environment and health

HOME | ENVIRONMENTAL RESEARCH | POLICY FRAMEWORK | EUROPEAN RESEARCH AREA | INTERNATIONAL COOPERATION | SME PARTICIPATION | SEARCH

RESEARCH AREAS

- Climate change
- Natural hazards
- Environment and health**
- Natural resources management

The challenge

Environmental factors can have a negative impact on human health and opinion polls show that Europeans are increasingly concerned about this issue. In addition, there are worrying trends that reinforce this concern. Cancer rates are rising at around 1% per year, while fertility rates are declining in some countries. Allergies and asthma are also up around 5% per year. Air pollution and exposure to chemicals are commonly cited as possible causes, while potential risks stemming from emerging technologies like mobile phones and nanotechnology need to be carefully assessed. It is also becoming apparent that climate change can be associated with a variety of health effects, from those relating to heat and floods to those linked with changing distribution of infectious diseases.

Projects

- Key projects
- All projects

Events

- PROSUITE Final Conference 30 October 2013, Brussels
- 2nd GRF One Health Summit 17-20 November 2013,

http://cordis.europa.eu/p/ict/programme/challenge_en.html



[Home](#)

[Partner Search](#)

[Fit for Health](#) ▾

[News](#)

[Events](#)

[Downloads](#)

[Contact](#) ▾



What are you looking for ?



<http://it.orhealth.eu>

Horizon 2020 Partner Search

Publish your profile



Interested in participating in EU research project within Horizon 2020 /Health thematic?
Please describe your company/organization's research expertise and field of activity by filling the proposed form! Your profile will be entered in the Fit for Health 2.0 database. This will contribute to increase your international visibility and will help you find qualified research partners.

Edit your profile
Find related partner searches (Match Making)

Publish your partner search



Are you a coordinator of a research consortium preparing a project proposal for an open call in Horizon 2020 /Health thematic and looking for SME partners?
Are you a coordinator of a running research project and would you like to find expertise at a later stage of your project?
The Fit for Health 2.0 initiative can help you find suitable and competent partners. Please indicate in which topics you are preparing or conducting your project.

Click here to proceed now

Find your project partners



The Fit for Health database offers both profiles of SMEs and research institutes interested in becoming involved in Horizon 2020 research projects as well as partner searches of research consortia looking for SME partners.

Search in the database & Find your project partner

The project partner in charge of your file is:

FFH2.0_01_FFG/ETP - European and International Programmes - Austria (Austria)

User menu

Connected as:
Ms. Camilo



Search in the database

[Publish your Profile or Partner search](#)

[Search in the database](#)

[Personal information](#)

[End Session](#)




Project coordinated by the FFG - Austrian Research Promotion Agency, European and International Programmes

The Fit for Health project is funded by the European Commission



HORIZONTE 2020 | Orçamento (2014-2020) - Saúde





Saúde << Bio Economia

SFS-12-2014	Assessing the health risks of combined human exposure to multiple food-related toxic substances	d.l. 12-03-2014
SFS-15-2014	Proteins of the future	d.l. 12-03-2014
SFS-16-2015	Tackling malnutrition in the elderly	d.l. 24-02-2015



Saúde << Energia

LCE-02-2014	Developing the next generation technologies of renewable electricity and heating/cooling	d.l. 01-04-2014
LCE-12-2014	Demonstrating advanced biofuel technologies	d.l. 10-09-2014
LCE-02-2015	Developing the next generation technologies of renewable electricity and heating/cooling	d.l. 03-09-2014
LCE-12-2015	Demonstrating advanced biofuel technologies	d.l. 03-03-2015




Saúde << Segurança

DRS-02-2014	topic 2: Tools for detection, traceability, triage and individual monitoring of victims after a mass CBRNE contamination and/or exposure	d.l. 28-08-2014
DRS-04-2014	topic 4: Feasibility study for strengthening capacity-building for health and security protection in case of large-scale pandemics - Phase I Demo	d.l. 28-08-2014



Desafio Societal Saúde, Alterações Demográficas e Bem-estar (DS1) (2014, 2020)

*m leme taç o atra s a co ti aç o
 e e te s o e árias i icati as e o
 s o i cl as os rogramas e
 ra al o mas e e ter ali am
 arte o se fi a ciame to*



Concursos DS1

- IMI2
- EDCTP2
- AAL2

EIT

Sem co-financiamento pelos EM

Com co-financiamento pelos EM

IMI – icati a e icame tos o a ores


EDCTP – arceria e tre a E ro a e os ases em Dese ol ime to ara e saios cl icas

AAL – rograma o to Am ie tAssiste i i g

EIT – stit to E ro e e o aç o e ec ologia E el ecime to Acti o

IMI2 – Iniciativa Medicamentos Inovadores 2

arceria lico ri a a
 IMI 2008, 2017



1638M€ (DS1 H2020) + 1425M€ (EFPIA) + 213M€ (Membros Associados)



Proposta de Eixos de Acção (SRA IMI2**):

- A1 – Target validation and biomarker research (efficacy and safety)
- A2 - Adoption of innovative clinical trials paradigms
- A3 – Innovative medicines
- A4 – Patient tailored adherence programmes

Lista de medicamentos prioritários da OMS



08 July 2013



Preparação para o H2020 (I)

**omiss o
E ro eia**

*Estr t ra
formaç o
ale ários
Doc me tos oficiais*

Inscrevam-se

**H2020
Advisor Groups**

**Peritos
avaliadores**

**– o tos e
o tacto acio ais**

*formaç o
ormaç o
Aco sel ame to
isi ili a e
roc ra e arceiros
i terface com E etc*

Contactem

**Apoios
locais institucionais**

Contactem

**EE – E ter rise
E ro e et or**

*A oio s E – acesso a
o as o ort i a es e
merca o
ice ciame to e
tec ologias etc*



Projecto co-financiado pela Comissão Europeia

Enterprise Europe Network Portugal - 2011 - Todos os Direitos Reservados

Preparação para o H2020 – projectos europeus ao alcance de todos (II)

**Fit for Health
(20)**

*Formações
 e cursos
 BD parceiros
 iniciativas etc*

**Health -2-
Market**

*Ação e formação dos
 resultados e D
 Oportunidade em
 transferência e tecnologia etc*

ENTENTE

*Portal para a
 transferência e colocação
 de especialistas etc
 reforço das iniciativas etc*

Participem




tt fitfor health e



tt health market e





"It is not the strongest of the species that survives, nor the most intelligent that survives. It is the one that is the most adaptable to change."

Charles Darwin



oana Camilo (oana cami o ct t
onto de Contacto aciona C ara o esa io Societa Sa de,
teraç es emo r icas e em estar do RI E